8-K: Surgery Partners Reports Strong Q3 2024 Results, Reaffirms Full-Year Guidance

Surgery Partners announced a 14.3% increase in revenue and a 21.9% increase in adjusted EBITDA for the third quarter of 2024, while reaffirming its full-year guidance.

Summary

• Surgery Partners reported a 14.3% increase in revenue to $770.4 million for the third quarter of 2024, compared to $674.1 million in the same period last year.
• Same-facility revenues increased by 4.2%, driven by a 0.5% increase in revenue per case and a 3.7% increase in same-facility cases.
• The company's adjusted EBITDA for the quarter was $128.6 million, a 21.9% increase from $105.5 million in the prior year period.
• Adjusted EBITDA margin expanded by 100 basis points to 16.7%.
• For the first nine months of 2024, revenue increased by 12.1% to $2,249.9 million, and adjusted EBITDA was $344.4 million.
• The company reaffirmed its full-year 2024 revenue guidance of greater than $3.075 billion and adjusted EBITDA guidance of greater than $508 million.
• Surgery Partners had $222 million in cash and $596 million in revolver capacity at the end of the quarter.
• The company's net loss attributable to Surgery Partners, Inc. was $31.7 million for the quarter.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with strong revenue and EBITDA growth, but the net loss and decrease in operating cash flow temper the overall sentiment. The reaffirmation of full-year guidance is a positive sign.

Positives

• The company experienced strong revenue growth of 14.3% in the third quarter.
• Adjusted EBITDA saw a significant increase of 21.9% in the third quarter.
• The company's adjusted EBITDA margin improved by 100 basis points.
• Same-facility cases grew by 3.7%, indicating organic growth.
• Surgery Partners reaffirmed its full-year revenue and adjusted EBITDA guidance.
• The company has a strong liquidity position with $222 million in cash and $596 million in revolver capacity.
• The company's balance sheet is positioned to support future growth opportunities.

Negatives

• The company reported a net loss attributable to Surgery Partners, Inc. of $31.7 million for the third quarter.
• Cash flows from operating activities decreased to $65.2 million in the third quarter of 2024, compared to $104.6 million in the prior year quarter.
• Year-to-date operating cash flows were $188.7 million compared to $231.2 million in the prior year period.

Risks

• The company faces risks related to reductions in payments from government health care programs and private insurance payors.
• There are risks associated with maintaining relationships with physicians and attracting new physician partners.
• The company is exposed to supply chain issues, including shortages or quality control issues with surgery-related products.
• Competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts poses a risk.
• The company is subject to the impact of future legislation and other health care regulatory reform actions.
• Cybersecurity attacks or intrusions could impact the company's operations.
• The company's indebtedness could pose a risk.
• The social and economic impact of a pandemic, epidemic or outbreak of a contagious disease could affect the business.

Future Outlook

The company reaffirmed its full-year 2024 revenue guidance of greater than $3.075 billion and adjusted EBITDA guidance of greater than $508 million.

Management Comments

• Wayne DeVeydt, Executive Chairman of the Board, stated that the company is proud to report another quarter of strong growth in Adjusted EBITDA and revenue, both of which were in line with expectations.
• Eric Evans, Chief Executive Officer, noted that surgical case volume remained strong, particularly in higher acuity and strategically important growth areas.
• Dave Doherty, Chief Financial Officer, commented that the company's balance sheet can sustain future growth opportunities.

Industry Context

The results reflect the ongoing trend of surgical cases migrating to outpatient settings, which benefits companies like Surgery Partners. The company's focus on higher acuity cases and strategic acquisitions aligns with industry trends towards value-based care and cost-effective solutions.

Comparison to Industry Standards

• Surgery Partners' 14.3% revenue growth in Q3 2024 is strong compared to some of its peers in the healthcare services sector, such as Tenet Healthcare (THC) which reported a 7.1% increase in net operating revenues in their Q3 2024 results.
• The 21.9% growth in adjusted EBITDA is also notable, outperforming HCA Healthcare (HCA) which reported a 12.5% increase in adjusted EBITDA in their Q3 2024 results.
• The 100 basis point expansion in adjusted EBITDA margin to 16.7% is a positive sign, indicating improved operational efficiency, and is comparable to some of the top performing companies in the sector such as UnitedHealth Group (UNH) which reported an operating margin of 8.7% in Q3 2024.
• However, the net loss of $31.7 million is a concern, and needs to be compared to the profitability of other companies in the sector such as Community Health Systems (CYH) which reported a net loss of $107 million in Q3 2024, indicating that while Surgery Partners is not alone in experiencing losses, it is an area that needs improvement.
• The company's debt to EBITDA ratio of 3.8x is within the acceptable range for the industry, but it is important to monitor this metric closely as it can impact the company's financial flexibility.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue and EBITDA growth, as well as the reaffirmed full-year guidance.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) should continue to receive high-quality, cost-effective surgical care.
• Suppliers may see increased demand for their products and services.
• Creditors should be reassured by the company's strong liquidity position and reaffirmed guidance.

Next Steps

• Surgery Partners will hold a conference call on November 12, 2024, to discuss the results.
• The company will continue to focus on organic and inorganic growth strategies.
• The company will continue to monitor and manage its balance sheet to support future growth opportunities.

Key Dates

Keywords

Surgery Partners, Surgical Facilities, Adjusted EBITDA, Revenue Growth, Healthcare Services, Outpatient Surgery, Same-Facility Revenue, Financial Results, Third Quarter 2024, Guidance Reaffirmed